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http://www.biomedcentral.com/1471-2261/13/26RESEARCH ARTICLE Open AccessMicrovolt T wave alternans in adults with
congenital heart diseases characterized by right
ventricle pathology or single ventricle physiology:
a case control study
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Background: Among adults with congenital heart diseases (CHD) evaluation of sudden cardiac death (SCD) risk
remains a great challenge. Although microvolt T-wave alternans has been incorporated into SCD risk stratification
algorithm, its role in adults with CHD still requires investigation. We sought to determine the incidence of MTWA in
this specific group and its coincidence with ventricular arrhythmia (VA) and other clinical findings presumably
associated with SCD.
Methods: A case–control study was performed in which 102 patients with CHD characterized by right ventricle
pathology or single ventricle physiology (TGA, UVH, Ebstein’s anomaly, ccTGA, Eisenmenger syndrome, DORV, CAT,
unoperated ToF) were compared to 45 age- and sex-matched controls. All subjects underwent spectral MTWA test,
ambulatory ecg monitoring, cardiopulmonary test, BNP assessment. After excluding technically inadequate traces,
the remaining MTWA results were classified as positive(+), negative(−) and indeterminate(ind). Due to similar
prognostic significance MTWA(+) and (ind) were combined into a common group labeled ‘abnormal’.
Results: Abnormal MTWA was present more often in the study group, compared to controls (39.2% vs 2.3%,
p = 0.00001). Sustained ventricular tachycardia (sVT) was observed more often among subjects with abnormal
MTWA compared to MTWA(−): 19.4% vs 3.6%, p = 0.026. The patients with abnormal MTWA had a lower blood
saturation (p = 0.047), more often were males (p = 0.031), had higher NYHA class (p = 0.04), worse cardiopulmonary
parameters: %PeakVO2 (p = 0.034), %HRmax (p = 0.003). Factors proven to increase probability of abnormal MTWA
on multivariate linear regression analysis were: sVT (OR = 20.7, p = 0.037) and male gender (OR = 15.9, p = 0.001); on
univariate analysis: male gender (OR = 2.7, p = 0.021), presence of VA (OR = 2.6, p = 0.049), NYHA > I (OR = 2.06,
p = 0.033), %HRmax (OR = 0.94, p = 0.005), %PeakVO2 (OR = 0.97, p = 0.042), VE/VCO2slope (OR = 1.05, p = 0.037).
Conclusions: Abnormal MTWA occurs significantly more often in adults with the chosen forms of CHD than
among healthy subjects. The probability of abnormal MTWA increases in patients with malignant VA, in males and
among subjects with heart failure and cyanosis. MTWA might be of potential role in risk stratification for SCD in
adults with CHD.* Correspondence: ola.cieplucha@gmail.com
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A dynamic progress of pediatric cardiosurgery made survival
to adulthood possible for most patients with congenital heart
defects (CHD) [1-4]. Most die due to cardiovascular compli-
cations including a sudden cardiac death (SCD) that ac-
counts for 19%-30% of total mortality and is observedmainly
in patients with complex forms of CHD [1-6]. Majority, i.e.
75%-80%, of SCD is caused by ventricular fibrillation [5,6]
but still this heterogenous population lacks fine indications
for implantable cardioverter-defibrillator (ICD) therapy in
primary prophylaxis [7]. Ventricular arrhythmia (VA) among
these patients originates from myocardial fibrosis due to
cyanosis and insufficient intraoperative cardioprotection;
scars after ventriculotomy; hemodynamic changes resulting
in ventricular dilation and increased wall stress, consequen-
tially causing areas of electrical inhomogeneity within myo-
cardium [2,8]. Noninvasive risk stratification for arrhythmic
SCD is based on factors that possibly contribute to the afore-
mentioned pathological chain that includes presence of ma-
lignant VA during ecg ambulatory monitoring [5,9], heart
failure [10-12], or widening of QRS complex reflecting intra-
and interventricular delay [9]. Nevertheless, such manage-
ment still lacks accuracy.
Microvolt T wave alternans (MTWA) – an electrocar-
diographic phenomenon displaying inhomogeneity of the
myocardial repolarization process is a promising method
of VA risk evaluation in patients with ischemic and non-
ischemic cardiomyopathies [13-15], which has been re-
cently included into guidelines for the SCD prevention
(class IIa) [6]. It has been proven that the heterogeneity of
the intracardiac repolarization leads to dispersion of the
depolarizing wave, reentry phenomenon and, as a conse-
quence, initiation of the ventricular arrhythmia [6]. To
our best knowledge, there have been merely two studies
on spectral MTWA phenomenon in CHD patients pub-
lished so far, both concerning only pediatric population
[16,17]. Therefore, the aim of our study was to determine
the incidence of spectral MTWA among grown-up pa-
tients with the chosen forms of CHD characterized by
pathology within right ventricle or single ventricle physi-
ology. Moreover, we evaluated the coincidence between
MTWA and malignant and potentially malignant ven-
tricular arrhythmia, as well as other demographic and
clinical findings presumably associated with an increased
risk of malignant VA and SCD in the analyzed population.
Methods
The study group consisted of 102 consecutive patients (47
males) in sinus rhythm diagnosed with CHD characterized
by pathology within right ventricle or single ventricle
physiology, aged 18-75 years (mean 34.2 ± 13.6 years), of
whom 46 (45.1%) were operated on at the age of 0.5-32 -
years (mean 6.2 ± 6.3 years). None of them had indications
for ICD in secondary prophylaxis. Five patients (4.9%)presented with common arterial trunk (CAT), 9(8.8%) –
congenitally corrected transposition of the great arteries
(ccTGA), 6(5.9%) – double outlet right ventricle (DORV),
32(31.4%) - Ebstein’s anomaly, 9(8.8%) – Eisenmenger syn-
drome due to simple shunt lesions, 20(19.6%) – complete
transposition of the great arteries (TGA), 3(2.9%) – native
tetralogy of Fallot (ToF), 18(17.7%) – univentricular heart
(UVH) including 8 patients with tricuspid atresia, 3 –
ccTGA, 4 – double inlet left ventricle (DILV) and 3 – com-
mon atrioventricular canal (CAVC). Surgical correction
was performed in 2 (40%) patients with CAT, 6 (100%)
with DORV, 2 (6.2%) with Ebstein anomaly, 18 (90%) with
TGA (using method of intraatrial repair), 12 (66.6%) with
UVH (including 11 Fontan operations and 1 pulmonary
banding). The control group consisted of 45 healthy volun-
teers (23 males) aged 18-65 years (mean 31.0 ± 9.2 years).
The exclusion criteria were: persistent atrial fibrillation,
permanent cardiac pacing, serum creatinine > 140 μmol/l,
serum aspartate transaminase level exceeding twice the
upper limit of normal, pulmonary diseases, mental or phys-
ical disability preventing cooperation. Functional status
was assessed according to the New York Heart Association
(NYHA) classification. Pulse oximetry was used to measure
resting blood oxygen saturation (SO2).
Microvolt T wave alternans was analyzed in 102P during
treadmill test while receiving their usual medications, in-
cluding beta blocker therapy [18]. After careful skin prep-
aration high-resolution electrodes (Micro-V Alternans
Sensors, Cambridge Heart Inc.) were applied using Frank
orthogonal configuration. MTWA was recorded during a
heart rate (HR)-based exercise protocol using CH2000
(Cambridge Heart Inc., Bedford, MA, USA) with the use of
spectral method [14]. The test was considered positive if
the significant MTWA (i.e. alternans voltage ≥ 1.8 μV and
alternans ratio > 3.0) appeared at an onset HR ≤ 110 bpm,
was present for ≥1 min in any orthogonal lead or two ad-
jacent precordial leads and sustained as long as HR
remained above the patient specific onset HR. The test was
classified as negative if sustained MTWA was absent at
HR ≤ 110 bpm and if there was ≥1 min at HR ≥ 105 bpm
of artifact-free trace (noise level < 1.8 μV, ectopy < 10%).
Otherwise, the test was considered indeterminate and im-
mediately repeated in order to reduce the number of such
results. As generally accepted [18] indeterminate test may
be caused either by patient factors (including: 1) excessive
ectopy during exercise, 2) unsustained MTWA, 3) failure
to achieve HR = 105 bpm) or technical factors (including:
1) a noisy recording, 2) failure to maintain HR between
105-110 bpm for ≥1 min). The indeterminate results due
to technical factors were ultimately excluded from further
analysis. Considering similar prognostic significance of
tests classified as positive or indeterminate due to patient
factors they were combined into a common group labeled
‘non-negative’ [MTWA(non-)] i.e. abnormal.
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VIVID 7 GE Medical System device, using 1.5-2.5Hz
probe in 2D, M and Doppler modes. The diagnoses of
anatomical anomalies were set according to the current
recommendations of the European Society of Cardiology
(ESC) [7]. Alike in other studies [19] the diagnosis of
pulmonary arterial hypertension (PAH) was based on
echocardiography. The estimation of pulmonary arterial
pressure (PAP) was based on the peak velocity of the jet
of tricuspid regurgitation enabling to calculate right ven-
tricular systolic pressure (using the simplified Bernoulli
equation). After excluding pulmonary stenosis, PAP was
calculated as the sum of right ventricular systolic pres-
sure and right atrial pressure (estimated as 5-15 mmHg
depending on the diameter and respiratory variation of
the inferior vena cava). According to the current guide-
lines on PAH management, we considered the criterion
of estimated PAP ≥ 37 mmHg combined with additional
echocardiographic variables suggestive of PAH a suffi-
cient basis to set this diagnosis [20].
Cardiopulmonary exercise treadmill test was performed
according to the modified Bruce protocol (adding stage 0-
3 min, 1.7 km/h, 5% grading) and symptom limited. The
equipment was calibrated with a standard gas mixture
before each test. Patients were encouraged to continue
the exercise until the respiratory exchange ratio (RER)
exceeded 1. Oxygen uptake (PeakVO2), carbon dioxide
production (VCO2) and minute ventilation were measured
with breath by breath technique using Sensor Medics,
model Vmax29. Peak VO2 was defined as the average for
the last 20s of exercise and expressed as ml/kg/min and
ml/min, as well as the percentage ranges predicted for sex,
age, height and weight [21]. A ventilation/carbon dioxide
slope (VE/VCO2 slope) was assessed by linear regression
for the whole exercise. A standard 12-lead electrocardiog-
raphy was continuously recorded. Due to physical disabi-
lity cardiopulmonary test was not performed in three
patients.
Ambulatory 24-hour ECG monitoring was registered the
same day as other tests using system CardioScan12.0 Pre-
mier, Oxford, 12.4.0040a version. Additionally, all previous
results of ambulatory ECG available in the patient’s medical
records were analyzed for presence of VA, which was classi-
fied as: excessive ventricular ectopy (ventricular premature
beats – VPB ≥ 10/hour), episodes of nonsustained ventri-
cular tachycardia – nsVT (presence of ≥3 consecutive ven-
tricular beats at a rate greater than 100 bpm, terminating
spontaneously in less than 30s), episodes of sustained
ventricular tachycardia – sVT (ventricular tachycardia
greater than 30s in duration or hemodynamically unstable)
[6]. According to the classification regarding patients
with structural heart disease [6,22] this findings were di-
vided into two groups: potentially malignant ventricular
arrhythmia (VPB ≥ 10/hour and/or nsVT) and malignantventricular arrhythmia (sVT). For the purposes of analysis,
a group comprising of patients with any of the specified
forms of VA was created and labeled ‘VPB ≥ 10/hour/
nsVT/sVT’.
QRS duration was adopted as the longest value mea-
sured among all 12 leads in standard electrocardiogram.
Serum brain natriuretic peptide (BNP) level was mea-
sured in the venous blood samples taken after 15 min of
rest in supine position using the Abbott AxSYM Im-
munoassay system.
Statistical analysis. Continuous variables were summa-
rized by mean ± SD or median and minimal-maximal
values, depending on normality of distribution assessed
with Wilk-Shapiro test. Variables following normal distri-
bution were analyzed using Student’s t test or Welch test,
otherwise nonparametrical U Mann–Whitney test com-
paring two groups was used. Categorical variables are rep-
resented by frequencies and percentages. For 2 × 2 tables
chi-square test with Yates’s correction or Fisher’s exact test
were performed. Factors associated with non-negative
MTWA were assessed by logistic regression. Because
some subgroups were too small it was impossible to per-
form multivariable logistic regression model for all param-
eters entered into analysis. Two-tailed values of p < 0.05
were considered statistically significant. Analyses were
performed using the Statistica 7.0 package.
Informed consent was obtained from all subjects. Our
study protocol, as approved by the Ethics Committee of
University of Medical Sciences in Poznan, conformed to
the ethical guidelines of the 1975 Declaration of Helsinki.Results
The MTWA examination was performed in total of 102
patients and 45 healthy individuals. The MTWA(+) as well
as MTWA(ind) was significantly more frequent in the
study group than among controls (respectively: 18(17.6%)
vs 1(2.2%), p = 0.008 and 18(17.6%) vs 0(0.0%), p = 0.002)
(Table 1). Ultimately, 10 patients and 2 controls with
MTWA indeterminate due to technical factors were ex-
cluded from further calculations and the rest constituted
two groups under analysis.
As shown in Table 2 the number of males among pa-
tients with MTWA(+) and MTWA(non-) was significantly
higher than in MTWA(−) group (respectively: 72.2% vs
33.9%, p = 0.006 and 58.3% vs 33.9%, p = 0.03). Patients
with MTWA(non-) presented a higher NYHA class com-
paring to those with MTWA(−) [2.0(min1.0-max3.0) vs 1.0
(min1.0-max3.0), p = 0.04] and lower resting SO2 [94.5%
(min73-max100) vs (97%(min76-max100), p = 0.047].
Malignant ventricular arrhythmia occured significantly
more often in patients with abnormal compared to nega-
tive MTWA [7(19.4%) vs (2(3.6%), p = 0.026]. However,
comparison between incidence of other forms of VA
Table 1 Microvolt T wave alternans in the study and control groups
Study group (n = 102) Control group (n = 45) Study group vs control group p
MTWA(+) (%) 18 (17.6) 1 (2.2) 0.008
MTWA(ind) (%) 18 (17.6) 0 (0) 0.002
MTWA(noise) (%) 10 (9.8) 2 (4.4) 0.35
MTWA(−) (%) 56 (54.9) 42 (93.4) 0.00001
MTWA(non -) (%) 36 (35.3) 1 (2.2) 0.00001
MTWA(+) – positive result; MTWA(ind) - result indeterminate due to patient factors; MTWA(noise) – result indeterminate due to technical factors;
MTWA(−) –negative result; MTWA(non-) – non-negative (abnormal) result.
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sult did not show statistical significance (Table 3).
In our study group the incidence of negative MTWA
decreased along with the rise in NYHA scale (NYHA I
−60.7%, II −32.1%, III −7.2%). Cardiopulmonary test
showed that exercise tolerance measured with peak oxy-
gen consumption (expressed as percentage of predicted
values) was worse in patients with abnormal compared to
those with negative MTWA: %PeakVO2 ml/kg/min (57.4 ±
11.7% vs 64.7 ± 17.0%, p = 0.029), %PeakVO2 l/min (58.7 ±
15.4% vs 66.4 ± 17.1%, p = 0.034). The difference was also
revealed with regard to chronotropic response which was
worse among subjects with abnormal compared to normal
MTWA: HRmax (145.5 ± 26.1 bpm vs 160.1 ± 20.9
bpm, p = 0.016), %HRmax (81.4 ± 11.7% vs 88.8 ± 11.0%,
p = 0.003). Patients with MTWA(non-) also had higher
(reaching statistical significance) concentrations of serum
BNP [57.1 pg/ml(min23.3-max343.5) vs 42.2 pg/ml (min6.6-
max598.4), p = 0.052] (Table 4).
As shown in univariate logistic regression analysis







Males (%) 40 (43.5) 13 (72.2) 8 (44.4)
Age (years) 29 28 31,5
Median (18–75) (19–64) (20–75)
Min-max
Operated (%) 28 (27.5) 9 (50) 4 (22.2)
NYHA 1.0 2.0 2.0
Median (1.0-3.0) (1.0-3.0) (1.0-3.0)
Min-max
SO2 (%) 97 96 92.5
Median (69–100) (75–99) (73–99)
Min-max
Pulmonary hypertension (%) 11 (12.0) 1 (5.6) 7 (38.9)
Beta blocker (%) 25 (27.1) 7 (38.9) 3 (16.7)
QRS (ms) 120 120 135
MedianMin-max (80–200) (100–200) (100–18
MTWA(+) – positive result; MTWA(ind) – indeterminate result; MTWA(−) –negative rto increase probability of abnormal MTWA (OR= 6.4,
p = 0.029). This risk was also over twice as high in males
(OR = 2.7, p = 0.021), in patients with any form (malignant
and/or potentially malignant) of VA (OR= 2.6, p = 0.49)
and in NYHA class > I (OR = 2.06, p = 0.033). Cardiopulmo-
nary parameters also played a significant role, but to a lesser
extent: HRmax (OR= 0.97, p = 0.006), %HRmax (OR= 0.94,
p = 0.005), %PeakVO2 (OR= 0.97, p = 0.042), VE/VO2slope
(OR = 1.05, p = 0.037). A multivariate logistic regression
analysis with regard to the presence of abnormal MTWA
confirmed a significant predictive value of sVT (OR= 20.7,
p = 0.037) and male gender (OR = 15.9, p = 0.001).
Discussion
Among the analyzed patients with the chosen forms of
CHD characterized by pathology within right ventricle or
single ventricle physiology, positive as well as indeterminate
MTWA test were present in both 19.6%. These values
exceeded those observed in the control group: MTWA(+)
was present in 2.2% what corresponded with the results









19 (33.9) 21 (58.3) 0.006 0.031
29 29.5 0.782 0.620
(18–74) (19–22)
9 (50) 13 (36.1) 0.786 0.663
1.0 2.0 0.231 0.040
(1.0-3.0) (1.0-3.0)
97 94.5 0.151 0.047
(69–100) (73–100)
9 (16.1) 2 (5.6) 0.434 0.191
15 (26.8) 10 (27.8) 0.380 1.0
120 125 0.354 0.123
0) (80–200) (100–200)
esult; MTWA(non-) – non-negative result; SO2 – blood oxygen saturation.















VPB ≥ 10/h/nsVT (%) 23 (25.0) 3 (16.7) 9 (50.0) 11 (19.6) 12 (33.3) 1.0 0.217
sVT (%) 9 (9.9) 1 (5.7) 6 (33.3) 2 (3.6) 7 (19.4) 1.0 0.026
VPB ≥ 10/h/nsVT/sVT (%) 27 (29.3) 4 (22.2) 11 (61.1) 12 (21.8) 15 (41.7) 1.0 0.060
MTWA(+) – positive result; MTWA(ind) – indeterminate result; MTWA(−) – negative result; MTWA(non-) – non-negative result; VPB ≥ 10/h – excessive ventricular
ectopy; nsVT – non-sustained ventricular tachycardia; sVT – sustained ventricular tachycardia.
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MTWA phenomenon among adults with CHD, the only
comparison could be made to pediatric groups – Cheung
et al. [17] assessed MTWA in 49 children after tetralogy of
Fallot repair observing 14.2% positive and as much as 37%
indeterminate (including those caused by technical arti-
facts) results. Alexander et al. [16] showed the incidence of
positive MTWA in 14% and indeterminate – in 28% out of
50 pediatric patients with CHD, which came close to the
outcomes of our study.
It has been proven that the prognostic value of positive
and indeterminate results is comparable [15,18,25-27],
therefore the majority of analyses interpret currently these
results as a common group of non-negative, i.e. abnormal
MTWA. In our study abnormal tests were observed in
39.2% of patients, which is markedly less than the values








BNP (pg/ml) 45.1 41.9 64.4
Median (6.6-598.4) (23.3-150.8) (25.1-343.5)
Min-max
PeakVO2 (ml/kg/min) 23.9 ± 6.7 23.1 ± 5.5 21.5 ± 6.9
Mean ± SD
%PeakVO2 (ml/kg/min) 62.3 ± 17.3 57.6 ± 9.6 57.2 ± 13.9
Mean ± SD
PeakVO2 (l/min) 1.6 ± 0.6 1.6 ± 0.5 1.4 ± 0.7
Mean ± SD
%PeakVO2 (l/min) 64.0 ± 18.8 57.4 ± 12.7 60.0 ± 18.2
Mean ± SD
HRmax 154.3 ± 24.0 153.4 ± 27.0 137.1 ± 22.
Mean ± SD
%HRmax 85.9 ± 11.8 85.0 ± 10.8 77.6 ± 11.8
Mean ± SD
VE/VCO2slope 32 32.5 42
Median (22–60) (26–60) (26–59)
Min-max
MTWA(+) – positive result; MTWA(ind) – result indeterminate due to patient factors
natriuretic peptide; HRmax – maximal heart rate on exercise; PeakVO2 – peak oxygeadvanced left ventricular non-congenital heart failure and
reach 67%-73% [25-27]. Exercise capacity as well as age
had a distinctive impact on these populations – over half
(51.1%) of the analyzed group presented NYHA I func-
tional class (NYHA II – 39,1%, NYHA III – 9,8%) and ma-
jority of them were in their forties, whereas patients
assessed in the cited publications were in the sixth or
seventh decade of life.
Our study showed that incidence of the malignant VA
was significantly higher among patients with abnormal
compared to negative MTWA. Moreover, the presence
of sVT and, to a lesser extent, presence of any form of
VA significantly increased the risk of abnormal MTWA
phenomenon. However, similar findings were not con-
firmed by the study of pediatric CHD patients [17].
Ventricular arrhythmia registered on ambulatory ecg









42.2 57.1 0.247 0.052
(6.6-598.4) (23.3-343.5)
24.9 ± 6.9 22.3 ± 6.2 0.317 0.072
64.7 ± 17.0 57.4 ± 11.7 0.098 0.029
1.6 ± 0.6 1.5 ± 0.6 0.845 0.376
66.4 ± 17.1 58.7 ± 15.4 0.046 0.034
9 160.1 ± 20.9 145.5 ± 26.1 0.280 0.016
88.8 ± 11.0 81.4 ± 11.7 0.200 0.003
32 36 0.118 0.061
(22–58) (26–60)
; MTWA(−) – negative result; MTWA(non-) – non-negative result; BNP – brain
n uptake on exercise; VE/VCO2 slope – ventilation/carbon dioxide slope.
Table 5 Factors increasing probability of abnormal MTWA in uni- and multivariate linear logistic regression analysis
Univariable analysis Multivariable analysis
OR (95% CI) p OR (95% CI) p
sVT 6.4 (1.22 – 33.57) 0.029 20.74 (1.21 – 355.88) 0.037
Male gender 2.72 (1.15 – 6.46) 0.021 15.98 (3.20 – 79.74) 0.001
VPB ≥ 10/h/nsVT/sVT 2.56 (1.01 – 6.51) 0.049 0.96 (0.23 – 4.05) 0.956
NYHA 2.06 (1.06 – 4.00) 0.033 2.38 (0.81 – 7.00) 0.115
VE/VCO2 slope 1.05 (1.00 – 1.10) 0.037 1.06 (0.98 – 1.14) 0.154
HRmax 0.97 (0.95 – 0.99) 0.006 0.99 (0.96 – 1.02) 0.421
%HRmax 0.94 (0.91 – 0.98) 0.005 - -
%PeakVO2 (l/min) 0.97 (0.94 – 0.99) 0.042 1.03 (0.98 – 1.09) 0.202
sVT – sustained ventricular tachycardia; VPB ≥ 10/h – excessive ventricular ectopy; nsVT – non-sustained ventricular tachycardia; VE/VCO2slope – ventilation/carbon
dioxide slope; HRmax - maximal heart rate on exercise; PeakVO2 – peak oxygen uptake on exercise.
Cieplucha et al. BMC Cardiovascular Disorders 2013, 13:26 Page 6 of 8
http://www.biomedcentral.com/1471-2261/13/26this population, this however might be linked to a low
number of such tests performed [1,28]. Nevertheless, the
prognostic value of Holter ecg refines when interpreted
together with other clinical features conducive to malig-
nant arrhythmia [28].
Therefore, our analysis was extended in order to deter-
mine which demographical and clinical features of pos-
sible prognostic value for SCD are characteristic for
patients with abnormal MTWA. It has been shown that
majority of subjects with non-negative result were males
and male gender turned out to be a factor of a higher
probability of this abnormal electrical phenomenon on
multivariate regression analysis. As already proven men
are more prone to die of SCD than women [6]. More-
over, male gender is also an acknowledged risk factor for
life-threatening VA [29,30] as well as total mortality [1]
among patients with CHD.
Patients with different MTWA results did not differ
with regard to age. SCD incidence in general population
increases one hundred-fold after 35th year of life [6], but
in the analyzed population heart disease is present since
birth and it is rather the complexity of a given defect
that determines patient’s later medical history. Previous
cardiosurgery did not influence patients’ MTWA results,
but the study group included subjects with various
anatomical cardiac anomalies that were operated with
various methods. Therefore, patients who underwent a
cardiosurgery (e.g. with Fontan method) did not neces-
sarily exhibited better clinical outcome than unoperated
patients with other anomalies.
Although widening of QRS complex plays a role in
SCD risk stratification [9,31], our study demonstrated no
significant difference in this parameter with regard to
the presence of MTWA phenomenon.
MTWA outcomes in the context of patients’ exercise
tolerance are worth focusing on as heart failure has been
found to predict malignant VA and SCD in the popula-
tion of CHD [7,30]. In this specific group not only leftventricular function becomes impaired, but often also
morphologically right systemic ventricle, both of the
chambers, or the so called single ventricle may become
dysfunctional. We observed that the number of patients
with negative MTWA systematically decreased between
NYHA I and NYHA III groups. Higher NYHA class was
also found to increase the probability of abnormal MTWA
phenomenon. It has been proven that deterioration of
patients’ functional status assessed with this classification
has an adverse prognostic value with regard to SCD in
this population [32-34], what suggests a potential role of
MTWA assessment in the risk stratification algorithms
[10]. Despite some methodological objections (lack of
objective assessment), NYHA classification remains the
most widely used tool to assess heart failure symptoms,
including adults with CHD. Although our study group
consisted of patients with complex forms of CHD, over
half of them (51,1%) was rated as NYHA class 1. Similar
results were obtained by other investigators – NYHA class
1 was reported by Piran et al. [35] in 40% of subjects with
single or systemic right ventricle (mean age 28,6 ± 7,8 -
years), whereas Diller et al. [11] classified 49% of patients
with different complex forms of CHD (mean age 33 ± 13 -
years) as being asymptomatic. Common underestimation
of patients’ self-reported functional status is mostly caused
by lifelong adaptations to their heart disease and not being
aware of slowly progressing exercise intolerance. Add-
itionally, relatively young mean age of our study group
(34,2 ± 13,6 years) makes NYHA Class 1 truly more pos-
sible as the symptoms of heart failure have not emerged
yet. In contrast, the study conducted by Bolger et al. [36]
among adults with complex CHD aged 33,5 ± 1,5 years re-
vealed NYHA class 1 and 2 in, respectively, 21% and 59%
of subjects. An explanation of such difference when com-
pared to our results may be the fact that study group en-
rolled by us in almost one third consisted of patients with
Ebstein syndrome, who are considered as being asymp-
tomatic over decades [7], whereas this defect was not
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in such a heterogenous and not numerous population
generalization and unequivocal conclusions are hardly
possible.
The study design included also more reliable method of
exercise tolerance evaluation i.e. cardiopulmonary test.
The conclusions drawn from the analysis of these parame-
ters were congruent with the findings based on NYHA
classification - a significantly worse exercise capacity was
observed among patients with abnormal MTWA com-
pared to those with negative test, which manifested as
lower peak oxygen uptake and worse chronotropic re-
sponse in the former group. The mentioned parameters as
well as an increased ventilatory respiratory workload (VE/
VCO2 slope) raised the probability of abnormal MTWA
in the analyzed group. Differences in BNP concentrations
among groups varying with regard to MTWA result were
not shown in our study.
Elevated pulmonary pressure along with decreased tissue
oxygenation also contributes to the pathogenesis of heart
failure among CHD patients [10], but since these phenom-
ena often coexist, it is merely possible to analyze them
separately [12]. In our trial patients with abnormal MTWA
did not diverge from the rest in the incidence of pulmonary
hypertension, but they were characterized by a markedly
lower blood saturation. Experts’ opinion emphasizes that
long-term cyanosis causes myocardial fibrosis which subse-
quently creates an arrhythmogenic substrate [12,34,37].
Study limitations
Our cohort is considerably smaller than those selected in
previous studies on the prognostic value of MTWA, albeit
due to the CHD population characteristics, most of
performed clinical trials deal with heterogeneity and lim-
ited number of patients. As a consequence, the main limi-
tation of our trial is lack of prospective evaluation of
MTWA prognostic value with regard to SCD risk among
adults with CHD. Taking into account a small number of
patients combined with a low expected number of SCD
per year, a statistically well-designed study would require
to last at least 10 years [8,37]. Therefore, our analysis will
be continued using mortality and arrhythmic end points
and for the moment conclusions on the role of MTWA in
CHD population can only be drawn indirectly, considering
general knowledge on arrhythmic SCD and the data
obtained in the study. On the basis of the results pre-
sented in our study one may also make an attempt to nar-
row down the group of adults with CHD who should
undergo a careful evaluation of indications for ICD ther-
apy, including MTWA test.
Conclusions
Abnormal spectral MTWA occurs significantly more
often in the population of adults with congenital heartdisease characterized by pathology within right ventricle
or single ventricle physiology compared to healthy
subjects.
The probability of its presence increases in patients with
malignant ventricular arrhythmia and among subjects
with clinical findings possibly related to lethal arrhythmia
including advanced heart failure and cyanosis. Male gan-
der is also associated with abnormal MTWA.
MTWA analysis might be of potential role in risk
stratification algorithms for sudden cardiac death in this
population, although further investigation in this field is
required.
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